Citius Oncology - Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

During the quarter ended June 30, 2026, the number of new institutions increased 78% compared with the prior quarter. Vials ordered by institutions from wholesalers rose 31% during the quarter. Subsequent to the quarter ended June 30, 2026, following an increase in both the number of ordering institutions and vial demand, orders from wholesalers have begun to reflect this incremental demand. Citius revenue is recognized when wholesale orders for LYMPHIR are placed and filled.

https://citiusonc.com/news/news-details/2026/Citius-Oncology-Reports-Strong-Commercial-Momentum-for-its-Cancer-Treatment/default.aspx